FibroGen regains rights to anemia drug from AstraZeneca

Kyntra Bio

26/02/2024 21:15

Feb 26 (Reuters) - FibroGen Inc  FGEN.O  said on Monday
it is regaining rights to the anemia drug, roxadustat, from
AstraZeneca  AZN.L  after the companies mutually agreed to
terminate their collaboration agreement.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh
Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))